GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Azitra Inc (AMEX:AZTR) » Definitions » EV-to-EBIT

Azitra (Azitra) EV-to-EBIT : -0.49 (As of May. 04, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Azitra EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Azitra's Enterprise Value is $5.42 Mil. Azitra's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.10 Mil. Therefore, Azitra's EV-to-EBIT for today is -0.49.

The historical rank and industry rank for Azitra's EV-to-EBIT or its related term are showing as below:

AZTR' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.23   Med: -0.25   Max: 0.16
Current: -0.49

During the past 3 years, the highest EV-to-EBIT of Azitra was 0.16. The lowest was -6.23. And the median was -0.25.

AZTR's EV-to-EBIT is ranked worse than
100% of 434 companies
in the Biotechnology industry
Industry Median: 8.915 vs AZTR: -0.49

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Azitra's Enterprise Value for the quarter that ended in Dec. 2023 was $10.22 Mil. Azitra's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.10 Mil. Azitra's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -108.59%.


Azitra EV-to-EBIT Historical Data

The historical data trend for Azitra's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Azitra EV-to-EBIT Chart

Azitra Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
- - -0.92

Azitra Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only - - -2.99 -1.17 -0.92

Competitive Comparison of Azitra's EV-to-EBIT

For the Biotechnology subindustry, Azitra's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Azitra's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Azitra's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Azitra's EV-to-EBIT falls into.



Azitra EV-to-EBIT Calculation

Azitra's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=5.424/-11.098
=-0.49

Azitra's current Enterprise Value is $5.42 Mil.
Azitra's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Azitra  (AMEX:AZTR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Azitra's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-11.098/10.219792
=-108.59 %

Azitra's Enterprise Value for the quarter that ended in Dec. 2023 was $10.22 Mil.
Azitra's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Azitra EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Azitra's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Azitra (Azitra) Business Description

Traded in Other Exchanges
N/A
Address
21 Business Park Drive, Branford, CT, USA, 06405
Anitra Inc is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. The company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen the library of strains for drug-like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains.
Executives
Fletcher Aaron G.l. 10 percent owner 40 GUEST STREET, BOSTON MA 02135
Leslie W. Kreis 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Andrew Mcclary director 21 BUSINESS PARK DRIVE, BRANFORD CT 06405
Aktiengesellschaft Bayer 10 percent owner BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368
Norm Staskey officer: Chief Financial Officer 21 BUSINESS PARK DRIVE, BRANFORD CT 06405
Bios Azitra Co-invest I, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bayer Us Holding Lp 10 percent owner 100 BAYER BOULEVARD, WHIPPANY NJ 07981
Bayer Healthcare Llc 10 percent owner
Francisco D. Salva director, officer: President and CEO 4500 GREAT AMERICA PKWY, STE. 100 #29, SANTA CLARA CA 95054
Travis Whitfill director, officer: Chief Operating Officer C/O IN8BIO,INC., 79 MADISON AVENUE, NEW YORK NY 10016
Bios Equity Partners Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Qp, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Fund Iii Nt, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107
Bios Capital Management, Lp 10 percent owner 1751 RIVER RUN, SUITE 400, FORT WORTH TX 76107